Characteristic	All patients (n=24) Median (range) / n (%)
Age / Male patient	45(24-68) / 12(50%)
Diagnosis AML / MDS / ALL / NHL / Other	9(37.5%) / 7(29.2%) /1(4.2%) / 4(16.7%) / 3(12.5%)
Donor: Related / Unrelated 9/10 / Unrelated 10/10	12(50%) / 3(12.5%) / 9(37.5%)
Conditioning regimen: Myeloablative / RIC	9(37.5%) / 15(62.5%)
Time (months) from SCT to cGVHD and from cGVHD to Imatinib	8(2-54) and 14(0-82)
GVHD sites involved at Imatinib treatment: Skin / Sclerodermal features / Eyes / Mouth / Liver / Lung Joint or fascia	17(70.8%) / 16(66.7%) / 6(25%) / 5(20.8%) / 1(4.2%) / 12(50%) / 11 (45.8%)
Prednisone at Imatinib treatment	7(29.1%)
NIH global score at Imatinib treatment: moderate/severe	9(37.5%) / 15(62.5%)
Other treatment at Imatinib therapy: Topical treatment / ECP / Tacrolimus / Cyclosporin / Sirolimus / Oral steroids / Methotrexate	2(8.3%) / 2 (8.3%) / 13 (54.2%) / 3 (12.5%) / 10(41.7%) / 7 (29.1%) / 2(8.3%)